Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of RPL10 inhibitor in preparation of medicine for treating ovarian cancer

An inhibitor, ovarian cancer technology, applied in the field of ovarian cancer gene therapy, can solve problems such as unrelated research, achieve the effect of promoting cell apoptosis and good drug development prospects

Active Publication Date: 2017-09-22
JINSHAN HOSPITAL FUDAN UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing studies have shown that RPL10 is highly expressed in the ovary of Penaeus monodon, but there is no related research in human ovarian tissue and ovarian tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of RPL10 inhibitor in preparation of medicine for treating ovarian cancer
  • Application of RPL10 inhibitor in preparation of medicine for treating ovarian cancer
  • Application of RPL10 inhibitor in preparation of medicine for treating ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] 1. Synthesis of RPL10-siRNA

[0033] 1. RPL10-siRNA sequence information

[0034] RPL10-humo-339S1:

[0035] sense (5'-3'): 5'CAUGGUGUCAGAUGAAUAU 3' (SEQ ID NO:1)

[0036] antisense (5'-3'): 5'AUAUUCAUCUGACACCAUG 3' (SEQ ID NO:2)

[0037] RPL10-humo-388S2:

[0038] sense (5'-3'): 5'GCCCGAAUUUGUGCCAAUA 3' (SEQ ID NO:3)

[0039] antisense (5'-3'): 5'UAUUGGCACAAAUUCGGGC 3' (SEQ ID NO:4)

[0040] RPL10-humo-723S3:

[0041] sense (5'-3'): 5'GUCCACCUAUGUCUUUGUA3' (SEQ ID NO:5)

[0042] antisense (5'-3'): 5'UACAAAGACAUAGGUGGAC3' (SEQ ID NO: 6)

[0043] TT was added to the 3' end of each of the above sequences to enhance its stability.

[0044] 2. RPL10-siRNA-388S2 has the best silencing effect

[0045] Ovary cancer cells OVCAR-3 were plated for 24 hours and transfected with RPL10-siRNA and control group C-siRNA (Roche X-tremeGENE siRNA transfection reagent 10 μl + siRNA 2 μg), and protein was extracted 48 hours after transfection. see results figure 1 , it can be se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of RPL10 inhibitor in preparation of a medicine for treating ovarian cancer. The fact that after RPL10 is knocked out, proliferation, migration and invasion of ovarian cancer cell strains can be inhibited and cell apoptosis is promoted is found; after over-expression of the RPL10, proliferation, migration and invasion of the ovarian cancer cell strains can be promoted and cell apoptosis is reduced; the RPL10 is prompted to have an effect of inhibiting occurrence and development of the ovarian cancer; the RPL10 also can be used as a new emerging treatment target point to reduce the expression of the RPL10 for ovarian cancer patients undergoing high expression of RPL10, and a potential treatment effect is achieved. The RPL10 inhibitor can be used for preparing the medicine for treating the ovarian cancer. The invention also provides siRNA having a remarkable RPL10 knock-down effect, which has a good drug development prospect.

Description

technical field [0001] The invention relates to the field of gene therapy of ovarian cancer, in particular to the application of RPL10 inhibitors in the preparation of drugs for treating ovarian cancer. Background technique [0002] Ovarian cancer is one of the common malignant tumors of female reproductive organs. Its incidence ranks third after cervical cancer and uterine body cancer, and it poses a serious threat to women's lives. The treatment of ovarian cancer mainly includes surgery, chemotherapy and radiotherapy, but it is difficult to cure it completely. In addition, the prognosis is extremely poor due to recurrence, drug resistance, and side effects of radiotherapy and chemotherapy. How to improve the survival rate of ovarian cancer patients and reduce the tumor recurrence rate has become a hot spot in clinical research at this stage. [0003] In recent years, with the development of molecular biology, immunology and virology, gene therapy has developed rapidly. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K48/00A61K31/713C12N15/113A61P35/00A61P35/04
CPCA61K31/713A61K45/00C12N15/1135C12N2310/11C12N2310/14
Inventor 许国雄史继敏张劲国张凌云
Owner JINSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com